MTOR and acute lymphoblastic leukemia: The potential of ORI with imatinib was reported on Ph(+) acute lymphoblastic leukemia cells where ORI hindered LYN/mTOR signaling pathway activation and indicated a mutual antileukemia effect with imatinib (Guo et al., 2012b).